Welcome to our dedicated page for Lisata Therapeutics news (Ticker: LSTA), a resource for investors and traders seeking the latest updates and insights on Lisata Therapeutics stock.
Lisata Therapeutics, Inc. develops investigational therapies for advanced solid tumors and other serious diseases. Its principal product candidate, certepetide, is a proprietary iRGD cyclic peptide designed to activate an uptake pathway that can improve tumor targeting and penetration by co-administered or tethered anti-cancer agents.
Recurring Lisata news covers clinical and preclinical data involving certepetide, collaborations and license agreements tied to antibody-drug conjugates and other delivery technologies, development-rights changes for regional markets, financial results, business updates, and corporate matters affecting governance or capital structure.
Lisata Therapeutics, Inc. reported strong first-quarter 2024 financial results and provided an update on its business activities. The company is anticipating pivotal data readouts from the Phase 2b ASCEND trial later in 2024, with transformative potential. They have received significant regulatory designations for their investigational drug certepetide in various cancer types. Lisata's financial management allows operations to be funded until early 2026. The company is executing multiple ongoing and planned clinical trials globally to advance their innovative therapies.
Lisata Therapeutics, Inc. (Nasdaq: LSTA) will participate in several industry and investor events in May 2024, including the Pharma Partnering U.S. Summit, BioNJ BioPartnering Conference, Pharma Partnering EU Summit, 10th Annual Oncology Innovation Forum, and the 2024 ASCO Annual Meeting. The Company aims to showcase its innovative therapies for advanced solid tumors and serious diseases, with key representatives like Tariq Imam and David J. Mazzo presenting at these events.
Lisata Therapeutics, Inc. (Nasdaq: LSTA) will release its financial results for the first quarter of 2024 on May 9, 2024. The company focuses on developing therapies for solid tumors and serious diseases. A conference call will follow the release, with a webcast available for replay on the company's website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.